-
Communities
-
Explore Vanderbilt communities
By latest
Featured community
Creative Data Solutions (CDS) is a Vanderbilt Shared Resource and has extensive experience in providing effective and robust solutions to challenges pertaining to research data using modern informatics and bioinformatics approaches.
-
- Resources
-
People
-
Publications
-
Explore publications
-
Keyword Connections
Connections to Receptor, ErbB-2 are shown below. Double-click or tap a node for more information.
Please note that publication matches are limited to 40 in this view. If you expected more, please view all publication matches for Receptor, ErbB-2.
Members
- No matching connections
Resources
- No matching connections
Communities
- No matching connections
Publications
- ERBB2 inhibition and heart failure.
Cote GM, Sawyer DB, Chabner BA
(2012) N Engl J Med 367: 2150-3 - ERBB2 inhibition and heart failure.
Cote GM, Sawyer DB, Chabner BA
(2013) N Engl J Med 368: 876 - Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J
(2012) Nature 487: 505-9 - New driver mutations in non-small-cell lung cancer.
Pao W, Girard N
(2011) Lancet Oncol 12: 175-80 - ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.
Arteaga CL, Engelman JA
(2014) Cancer Cell 25: 282-303 - Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?
Arteaga CL, Baselga J
(2004) Cancer Cell 5: 525-31 - HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL
(2006) Cancer Cell 10: 25-38 - Synergistic and tunable human gene activation by combinations of synthetic transcription factors.
Perez-Pinera P, Ousterout DG, Brunger JM, Farin AM, Glass KA, Guilak F, Crawford GE, Hartemink AJ, Gersbach CA
(2013) Nat Methods 10: 239-42 - Human epidermal growth factor receptor 2 testing in breast cancer: 30% versus 10% cutoff for immunohistochemistry.
Hameed O, Chhieng D, Adams AL
(2008) J Clin Oncol 26: 1571 - HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA
(2017) J Clin Oncol 35: 446-464 - Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, Ji H
(2010) J Clin Oncol 28: 4616-20 - Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL
(2014) J Clin Oncol 32: 1202-9 - Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome.
Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL, American Society of Clinical Oncology, College of American Pathologists
(2007) J Clin Oncol 25: 5418-25 - Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC
(2013) J Clin Oncol 31: 1726-31 - Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL
(2008) J Clin Oncol 26: 897-906 - Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy.
Rexer BN, Shyr Y, Arteaga CL
(2013) J Clin Oncol 31: 2073-5 - Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM
(2002) Circulation 105: 1551-4 - Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
Goetz MP, Sun JX, Suman VJ, Silva GO, Perou CM, Nakamura Y, Cox NJ, Stephens PJ, Miller VA, Ross JS, Chen D, Safgren SL, Kuffel MJ, Ames MM, Kalari KR, Gomez HL, Gonzalez-Angulo AM, Burgues O, Brauch HB, Ingle JN, Ratain MJ, Yelensky R
(2014) J Natl Cancer Inst 107: - Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.
Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W
(2000) J Natl Cancer Inst 92: 412-7 - Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN
(2001) Gastroenterology 120: 1713-9 - Activation of EGFR and ERBB2 by Helicobacter pylori results in survival of gastric epithelial cells with DNA damage.
Chaturvedi R, Asim M, Piazuelo MB, Yan F, Barry DP, Sierra JC, Delgado AG, Hill S, Casero RA, Bravo LE, Dominguez RL, Correa P, Polk DB, Washington MK, Rose KL, Schey KL, Morgan DR, Peek RM, Wilson KT
(2014) Gastroenterology 146: 1739-51.e14 - Diverse expression of ErbB receptor proteins during rat liver development and regeneration.
Carver RS, Stevenson MC, Scheving LA, Russell WE
(2002) Gastroenterology 123: 2017-27 - C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
Kern JA, Slebos RJ, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D, Schwartz DA
(1994) J Clin Invest 93: 516-20 - The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J
(2008) J Clin Invest 118: 64-78 - TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL
(2013) J Clin Invest 123: 1348-58 - ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RS
(2013) J Clin Invest 123: 4329-43 - Inhibitory role of alpha 6 beta 4-associated erbB-2 and phosphoinositide 3-kinase in keratinocyte haptotactic migration dependent on alpha 3 beta 1 integrin.
Hintermann E, Bilban M, Sharabi A, Quaranta V
(2001) J Cell Biol 153: 465-78 - Genomic profiling of ER breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.
Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, Gόmez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL
(2017) Sci Transl Med 9: - An Acquired Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL
(2017) Cancer Discov 7: 575-585 - HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W
(2012) Cancer Discov 2: 922-33 - Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis.
Yamaoka T, Yan F, Cao H, Hobbs SS, Dise RS, Tong W, Polk DB
(2008) Proc Natl Acad Sci U S A 105: 11772-7 - Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas.
Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, Page DL
(1991) Proc Natl Acad Sci U S A 88: 10435-9 - Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue.
Gerdes MJ, Sevinsky CJ, Sood A, Adak S, Bello MO, Bordwell A, Can A, Corwin A, Dinn S, Filkins RJ, Hollman D, Kamath V, Kaanumalle S, Kenny K, Larsen M, Lazare M, Li Q, Lowes C, McCulloch CC, McDonough E, Montalto MC, Pang Z, Rittscher J, Santamaria-Pang A, Sarachan BD, Seel ML, Seppo A, Shaikh K, Sui Y, Zhang J, Ginty F
(2013) Proc Natl Acad Sci U S A 110: 11982-7 - Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase.
Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL
(2011) Proc Natl Acad Sci U S A 108: 5021-6 - Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors.
Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL
(2012) Proc Natl Acad Sci U S A 109: 2718-23 - Epidermal growth factor stimulates substrate-selective protein-tyrosine-phosphatase activity.
Hernández-Sotomayor SM, Arteaga CL, Soler C, Carpenter G
(1993) Proc Natl Acad Sci U S A 90: 7691-5 - Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.
Red Brewer M, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W
(2013) Proc Natl Acad Sci U S A 110: E3595-604 - Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
Lenferink AE, Simpson JF, Shawver LK, Coffey RJ, Forbes JT, Arteaga CL
(2000) Proc Natl Acad Sci U S A 97: 9609-14 - Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL
(2001) Cancer Res 61: 8887-95 - Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics.
Reyzer ML, Caldwell RL, Dugger TC, Forbes JT, Ritter CA, Guix M, Arteaga CL, Caprioli RM
(2004) Cancer Res 64: 9093-100
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.
